Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Definium Therapeutics Inc. Common Shares (DFTX)

NASDAQ: DFTX · Medicinal Chemicals & Botanical Products · New York, NY

Our rating: Cautious

Cautious reaffirmed at $34.64, low conviction, November 10, 2026.

Breaks if: The cautious call is wrong if Definium reports a confirmed pivotal-trial success or regulatory approval within the next 12 months and the stock holds above $46.00 — roughly 33% above today's $34.64 — for at least 20 consecutive trading days following that disclosure. That combination would demonstrate pipeline value the available figures cannot support today.

Key figures

Market value$3.9B
Revenue, last 12 monthsn/a
Net income, last 12 months−$337M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.0%
Operating marginn/a
Return on equity−61.4%
Beta to the S&P 5001.56
Volatility, annualized75.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-0.46n/a
June 30, 2026n/an/a$-1.44n/a
March 31, 2026n/an/a$-0.71n/a
December 31, 2025n/an/a$-0.50n/a
September 30, 2025n/an/a$-0.78n/a
June 30, 2025n/an/a$-0.50n/a
March 31, 2025n/an/a$-0.35n/a
December 31, 2024n/an/a$-0.42n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

23 ledger entries and 21 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.